Lisinopril Capsules

Pharmacology This product is a competitive angiotensin converting enzyme inhibitor. It prevents angiotensin I from converting to angiotensin II, reduces aldosterone secretion, increases plasma renin activity, and inhibits the degradation of bradykinin, reducing vascular resistance. Clinical trials have shown that the antihypertensive effect of this product alone in African hypertensive patients (usually low renin) is lower than that of other patients. This product does not cause reflex tachycardia while lowering blood pressure. This product dilates arteries and veins, reduces peripheral vascular resistance or afterload, reduces pulmonary capillary wedge pressure or preload, and also reduces pulmonary vascular resistance, thereby improving cardiac output in patients with heart failure and prolonging exercise tolerance and time. Large-scale clinical trials have confirmed that early use of this product in patients with acute myocardial infarction can reduce mortality.

The chemical name of this product: 1-[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysinyl]-L-proline dihydrate. Its molecular formula: C21H31N3O4.2H2O, molecular weight: 441.52.

This product is a hard capsule, and the contents are white or off-white powder.

Hypertension (can be used alone or in combination with other antihypertensive drugs such as diuretics).

The absorption of this product is not affected by food and can be taken before, during or after meals, once a day.

Most patients tolerate this product well, with mild and short-term headaches, dizziness, fatigue, drowsiness, nausea, and cough being the most common. The most common reasons for discontinuation are headaches and coughs. Rare adverse reactions include: postural hypotension, syncope, erythema and fatigue, allergic/angioneurotic edema (occasionally occurring on the face, limbs, lips, tongue, glottis, and/or larynx). The following side effects are occasionally seen: Cardiovascular system: ischemic heart disease or cerebrovascular disease (when the patient's blood pressure drops excessively, it leads to myocardial infarction or cerebrovascular accident, palpitations, tachycardia); Digestive system: abdominal pain, dry mouth, hepatocellular or cholestatic hepatitis, cirrhosis; Nervous system: emotional changes, confusion. Skin: urticaria, rash, sweating, photosensitivity or other skin symptoms; Urogenital system: uremia, decreased urine volume/anuria, renal insufficiency, acute renal failure, impotence; Others: fever, vasculitis, myalgia, joint neuralgia/arthritis; Laboratory tests: increased blood urea and serum creatinine, slightly decreased hemoglobin and hematocrit, positive antinuclear antibodies, accelerated erythrocyte sedimentation rate, increased eosinophils and leukocytosis, and hyperkalemia.

1. Those who are allergic to any ingredient of this product. 2. Those who have experienced angioedema due to the use of angiotensin-converting enzyme inhibitors. 3. Those with solitary kidney, transplanted kidney, bilateral renal artery stenosis and renal impairment.

Precautions for children: The dosage for children has not been determined and the research is insufficient. In newborns and infants, there is a risk of oliguria and neurological abnormalities, which may be related to the renal and cerebral ischemia caused by the product lowering blood pressure. Precautions for pregnancy and lactation: Pregnant women taking angiotensin-converting enzyme inhibitors can cause fetal and neonatal death. Once pregnancy is discovered, this product should be discontinued immediately. The use of angiotensin-converting enzyme inhibitors during pregnancy for 6-9 months can cause hypotension, skeletal dysplasia in newborns, anuria, reversible and non-reversible renal failure, and even death. It is not known whether this product is secreted in human breast milk. Precautions for the elderly: Age has no effect on the efficacy and safety of this drug. However, for the elderly with renal function decline, the dose of this drug should be reduced, and then adjusted according to the blood pressure.

1. Patients with heart failure who are taking cardiac glycosides and diuretics and who already have water and sodium deficiency should use a small dose when starting to use this product. 2. Combination with potassium-sparing diuretics such as spironolactone, triamterene, and amiloride may cause hyperkalemia, especially in patients with renal insufficiency. 3. Non-steroidal anti-inflammatory analgesics, especially indomethacin, can inhibit renal prostaglandin synthesis and cause water and sodium retention, weakening the antihypertensive effect of this product. 4. When used in combination with other antihypertensive drugs, it has a synergistic antihypertensive effect, among which it has a greater additive effect with drugs that cause renin release or affect sympathetic activity. 5. Combination with lithium salts can reduce the excretion of lithium salts, and the concentration of lithium salts must be monitored.

Keep in a light-proof and airtight container.

5mg

18 months

Jiangsu Tasly DIYI Pharmaceutical Co., Ltd.

• Founded in:

  1999-03-24

• Address:

  No. 168, Chaoyang West Road, Qingpu Industrial Park, Huai'an City

• Tax NO.:

  91320800139432975C

• Registered Funds:

  66.86 million yuan

• Website:

  Log in to view

• Email:

  Log in to view